No-observed effect levels are associated with up-regulation of MGMT following MMS exposure by Gareth, Jenkins
 Cronfa -  Swansea University Open Access Repository
http://cronfa.swan.ac.uk
 
 
Doak, S. Brusehafer, K.  & Dudley, E.  (2008). No-Observed Effect Levels are
Associated with Up-Regulation of MGMT Following MMS Exposure.. Mutat. Res.
(Fund. Mech.s), 648, 9-14.
 
 
 
 
Gareth Jenkins
College of Medicine, College of Medicine, Swansea University, Wales, SA2 8PP
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This article is brought to you by Swansea University. Any person downloading material is agreeing to abide by the
terms of the repository licence. Authors are personally responsible for adhering to publisher restrictions or conditions.
When uploading content they are required to comply with their publisher agreement and the SHERPA RoMEO
database to judge whether or not it is copyright safe to add this version of the paper to this repository. 
http://www.swansea.ac.uk/iss/researchsupport/cronfa-support/ 
 Mutation Research 648 (2008) 9–14
Contents lists available at ScienceDirect
Mutation Research/Fundamental and Molecular
Mechanisms of Mutagenesis
journa l homepage: www.e lsev ier .com/ locate /molmut
Communi ty address : www.e lsev ier .com/ locate /mutres
No-observed effect levels are associated with up-regulation
of MGMT following MMS exposure
Shareen H. Doaka,∗, Katja Brüsehafera, Ed Dudleyb, Emma Quicka, George Johnsona,
Russell P. Newtonb, Gareth J.S. Jenkinsa
a Institute of Life Science, School of Medicine, Swansea University, Singleton Park, Swansea, SA2 8PP, Wales, UK
b Biomolecular Analysis Mass Spectrometry Facility, Department of Environmental and Molecular Biosciences, School of the Environment and Society,
Swansea University, Singleton Park, Swansea, SA2 8PP, Wales, UK
a r t i c l e i n f o
Article history:
Received 7 May 2008
Received in revised form 31 July 2008
Accepted 4 September 2008
Available online 17 October 2008
Keywords:
O6-methylguanine DNA methyltransferase
N-methylpurine-DNA glycoslase
Thresholds
Methyl methanesulphonate
DNA adducts
DNA repair
a b s t r a c t
The alkylating agents methyl methanesulphonate (MMS) and ethyl methanesulphonate (EMS) have non-
linear dose–response curves, with a no-observed effect level (NOEL) and a lowest observed effect level
(LOEL) forbothgross chromosomaldamageandmutagenicity.However, thebiologicalmechanismrespon-
sible for the NOEL has yet to be identiﬁed. A strong candidate is DNA repair as it may be able to efﬁciently
remove alkyl adducts at low doses resulting in a NOEL, but at higher doses fails to fully remove all lesions
due to saturation of enzymatic activity resulting in a LOEL and subsequent linear increases in muta-
genicity. We therefore assessed the transcriptional status of N-methylpurine-DNA glycoslase (MPG) and
O6-methylguanine DNA methyltransferase (MGMT), which represent the ﬁrst line of defence following
exposure to alkylating agents through the respective enzymatic removal of N7-alkylG and O6-alkylG. The
relative MPG and MGMT gene expression proﬁles were assessed by real-time RT-PCR following expo-
sure to 0–2g/ml MMS for 1–24h. MPG expression remained fairly steady, but in contrast signiﬁcant
up-regulation of MGMT was observed when cells were treated with 0.5 and 1.0g/ml MMS for 4h (2.5-
and 6.5-fold increases respectively). These doses lie within the NOEL for MMS mutagenicity (LOEL is
1.25g/ml), thus this boost in MGMT expression at low doses may be responsible for efﬁciently repairing
O6methylG lesions and creating the non-linear response for mutations. However, as the LOEL for MMS
clastogenicity is 0.85g/ml, O6-alkylG is unlikely to be responsible for the clastogenicity observed at
these concentrations. Consequently, at low doses N7-methylG is possibly the predominant cause of MMS
clastogenicity, while O6-methylG is more likely to be responsible for MMS mutagenicity, with MGMT up-
regulation playing a key role in removal of O6-alkylG lesions before they are ﬁxed as permanent point
mutations, resulting in non-linear dose–responses for direct acting genotoxins.
© 2008 Elsevier B.V. All rights reserved.
1. Introduction
The shapes of dose–response curves provide important infor-
mation for risk assessments to enable the safety evaluation of
chemical agents. These curves may have a variety of shapes
[1] that all have different implications as they are dependent
upon multiple factors ranging from speciﬁc chemical characteris-
tics (such as mode of action), to cellular barriers including DNA
repair, metabolic activation or membranes that enclose and pro-
tect organelles [2]. However, for genotoxins that react directly with
DNA the classical assumption (for carcinogen classiﬁcation and
regulatory purposes) has been that a linear relationship prevails
∗ Corresponding author. Tel.: +44 1792 295388; fax: +44 1792 602147.
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with permanent genetic aberrations arising at any given level of
exposure [3]. This linear model has largely prevailed because for
most compounds the dose–response at low concentrations has not
been considered, so as a precautionary measure linear extrapo-
lations have been the default. We have recently challenged this
theory and demonstrated that certain alkylating agents, a classi-
cal group of electrophilic DNA reactive genotoxins, have non-linear
dose–responses with respect to both gross chromosomal damage
and mutagenicity [4]. Both methyl methanesulphonate (MMS) and
ethyl methanesulphonate (EMS) were shown to lack any signiﬁ-
cant biological consequence below a critical dose, resulting in a
no-observed effect level (NOEL) and a lowest observed effect level
(LOEL). MMS and EMS therefore demonstrated a LOEL for chromo-
somal damage at 0.85 and 1.4g/ml respectively, and for point
mutations at 1.25 and 1.4g/ml. Identiﬁcation of the biological
mechanism that is responsible for the NOEL is necessary to jus-
0027-5107/$ – see front matter © 2008 Elsevier B.V. All rights reserved.
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tify and corroborate its existence [5], and is currently lacking for
these compounds.
Despite the methanesulphonates demonstrating a non-linear
dose–response, their counterpart nitrosoureas had linear shaped
curves. This indicated that the governing factor was the alkyla-
tion target sites within the bases. The methanesulphonates are
high s-value alkylating agents that react with highly nucleophilic
centres, hence their primary targets are N7G, N3A and to a much
lesser extent O6G. In contrast, the nitrosoureas have low s-values
and so will target less nucleophilic centres, they are therefore
more potent alkylators of O6G, O2T and O4T [2,6]. This suggests
DNA repair may be strongly involved in inﬂuencing the shape
of the respective dose–response curves as N7G, N3A and O6G
have speciﬁc repair mechanisms associated with their removal,
while O2T and O4T are very poorly corrected [4]. Consequently,
at low methanesulphonate exposure levels, DNA repair is likely
to be primarily responsible for the efﬁcient removal of the N7G,
N3A and O6G DNA adducts resulting in a NOEL, while failing
to fully remove all the damage at higher concentrations due to
saturation of enzymatic activity resulting in a LOEL and subse-
quent dose dependent increases thereafter. With respect to the
nitrosoureas, it is possible that at low exposure levels, the N7G,
N3A and O6G may be repaired, but those at the O2T and O4T posi-
tions would persist, giving rise to the more linear dose–response
observed.
Cells have several DNA repair mechanisms, some of which are
capable of correcting speciﬁc types of damage. With respect to
alkyl-DNA adducts, O6-alkylG is primarily removed by the enzyme
O6-methylguanine DNA methyltransferase (MGMT) in a single-
step reaction [7,8]. The enzyme transfers the alkyl group from the
adducted base to an internal cysteine residue within the active
centre of the methyltransferase, resulting in its irreversible inac-
tivation, so one MGMT molecule will only remove one O6G adduct
[8]. MGMT expression is induced in response to DNA damage (one
regulatory pathway involves p53); a cells capacity to repair O6G
lesions is therefore dependent upon the rate atwhich it can synthe-
siseMGMT [9].MGMT ismost efﬁcient at removingmethyl adducts,
however it is capable of removing larger adducts (e.g. ethyl, propyl,
butyl adducts) although at a lower efﬁciency [8]. This enzyme is
therefore very important in the protection of DNA against alkylat-
ing agents. However if MGMT fails to remove the alkyl group and
the O6-alkylG persists, it may stably mispair with thymine in the
ﬁrst cycle of replication, resulting in a GC to AT transition mutation
in the subsequent cycle [10,11]. In addition to point mutations, O6-
alkylG is also associated with causing chromosomal damage as the
thymine placed opposite this lesion is subject to mismatch repair.
However, this repair isoften invainas theDNAadduct is still present
in the parental strand, so the result is a single-stranded gap that in
turn leads to double-strand breaks through stalled replication forks
[12].
Alkyl adducts that arise at the N7G position are also thought
to be precursors for both chromosomal damage and point muta-
tions as the modiﬁcation destabilises the N-glycosidic bond and
therefore they are prone to spontaneous depurination resulting in
abasic sites [7,13,14]. During replication these single-stranded gaps
are unprotected and can stall replication forks resulting in double-
stranded breaks, but if they are detected prior to replication, they
are subject to error prone repair leading to possible sequence aber-
rations [10,15]. However, N7-alkylG adducts are not considered to
be as mutagenic as O6-alkylG because the abasic sites are often
correctly repaired. Additionally, the N7-alkylG adducts are usually
removed by enzymatic hydrolysis of the N-glycosylic bond, catal-
ysedbyN-methylpurine-DNAglycoslase (MPG). This is theﬁrst step
in the initiation of repair of these lesions by the base excision repair
(BER) pathway [7,15,16].
In the present study, we have elected to investigate the mode
of action that underlies the non-linear dose–response that the
well known point mutagen and clastogen MMS demonstrates.
We ﬁrstly demonstrated that alkyl adducts are indeed present
following exposure to MMS doses within the NOEL by mass spec-
trometry, hence ruling out non-linear adduct formation. As MGMT
and MPG represent the ﬁrst line of defence against alkylation dam-
age, we then assessed their gene expression patterns. MGMT was
up-regulated suggesting its enhanced expression may have been
responsible for removing the alkylation damage before it was ﬁxed
as measurable mutations, resulting in the NOEL. However, at con-
centrations above the LOEL for MMS, enhanced MGMT expression
was not maintained, p53 activation was therefore also investigated
toprovide insights into its role inmodulatingMGMTtranscriptional
activity.
2. Materials and methods
2.1. Cell culture and treatment
The human lymphoblastoid B cell line AHH-1, was cultured in RPMI 1640 sup-
plemented with 10% foetal horse serum and 1% l-glutamine (Gibco, Paisley, UK) at
37 ◦C, 5% CO2. The cells were routinely sub-cultured to maintain a concentration of
1×105 cell/ml.
Cultures to be exposed to the alkylating agent were seeded at 1×105 cells/ml
for 24h and then treated with MMS (Sigma–Aldrich, Dorset, UK; CAS Registry Num-
ber 66-27-3) over a range of concentrations both above and below the previously
identiﬁed LOEL for point mutations (1.25g/ml) [4]. The duration of exposure was
24h for the mass spectrometry analysis, but 1, 2, 4, 6, or 24h for all other assays.
Following treatment cells were washed twice in PBS prior to DNA, RNA or protein
extraction. For each time point and at every dose, the experiment was repeated in
triplicate.
2.2. Mass spectrometry
DNA was isolated by a high salt extraction method (Stratagene, Amsterdam,
The Netherlands) and each samples’ concentration and purity was determined by
spectrophotometery.
Three hundred micrograms of each DNA sample were depurinated at 100 ◦C for
7min [17], allowed to cool andpassed through a30,000MWCOMicrocon centrifugal
ﬁlter (Millipore, Durham, UK). Following freeze-drying, samples were re-suspended
in 10l water. N7-methylguanine and N7-ethylguanine standards (NCI Chemical
Carcinogen Reference Standard Repository, Missouri, USA) were prepared at con-
centrations ranging from 10–10,000 fM per injection. The N7-methylguanine was
used to generate a standard curve, while the ethylguanine was used as an external
standard in the quantitative assay to normalise the data from different experiments,
thereby providing a robust and accurate quantitative assay. The samples and stan-
dards (3l) were injected onto a C18 PepMap100 column (LC Packings, Surrey, UK)
of length 25 cm, I.D. 300m, using anUltimate capillary LC (LC Packings, Surrey, UK)
system connected online with a Micromass Q-TOF Ultimate API Mass spectrometer
(Waters, UK). The LCwas usedwith an isocratic solvent ﬂowof 82% A (H2Owith 0.1%
CHOOH) and 18% B (MeOHwith 0.1% CHOOH)maintained at 4l/min. Acquisition of
mass spectrawas initiated by a signal sent by the LC system after injection. Themass
spectrometry performed two single reaction monitoring (SRM) acquisitions simul-
taneously: 1. Tandemmass spectrum(MS/MS)of theprotonatedmethylguanine (m/z
166) followed by the selective detection of the major product ion at m/z 149 and 2.
MS/MS of the protonated ethylguanine ion m/z 180 and detection of the product
ion at m/z 152. The operation settings were: capillary 3.00kV; cone 35; source tem-
perature 110 ◦C; desolvation temperature 120 ◦C; cone gas 200 l/min; desolvation
gas 250 l/min; collision gas 16. Methanol blanks were run after each DNA sample to
clean the column and avoid carry over.
2.3. Gene expression analysis
Total RNA was extracted utilising the RNeasy Mini Kit (Qiagen, Sussex, UK),
according to the manufacturers’ instructions. Residual DNA was removed by DNase
1 treatment (DNA-freeTM, Ambion Ltd., Cambridgeshire, UK), then the RNA concen-
tration, purity and quality was assessed by spectrophotometry.
Real-time reverse transcription-PCR (RT-PCR) was used to quantify the expres-
sion of MGMT, MPG and p21. One microgram RNA from each sample was reverse
transcribed into cDNA using oligo(dT) primers and the RETROscript kitTM (Ambion
Ltd., Cambridgeshire, UK). The initial denaturation step was omitted, but oth-
erwise manufacturers’ instructions were followed. Real-time RT-PCR was then
performed on an iCycler iQ Thermal Cycler (Bio-Rad, Hertfordshire, UK) as pre-
viously described [18]. Appropriate primer sets for the test genes were designed
to span an intron and validated to ensure they all had the same efﬁciency as
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the -actin internal control set: MGMT forward 5′-CTATCGAAGAGTTCCCCGTGCC-
3′ and reverse 5′-GCTGCTAATTGCTGGTAAGAAATCAC-3′; p21 forward 5′-GACTCT-
CAGGGTCGAAAACG-3′ and reverse 5′-GGATTAGGGCTTCCTCTTGG-3′; MPG forward
5′-CTTCTGCATGAACATCTCCAGC-3′ and reverse 5′-AGGGTGCTGCGAAGCTGACGC-3′ .
The resultant threshold cycle (CT) data was analysed by the 2−CT method
and normalised to the -actin housekeeping gene to determine the relative gene
expression changes in treated samples as compared to the control untreated samples
[19]. N-fold differences observed were only considered signiﬁcant changes in gene
expression if <0.5 or >1.5 as previously deﬁned [18]. Students paired T-test was
used to determine if up- or down-regulations proved to be signiﬁcant changes in
expression as compared to the control samples.
2.4. Western blotting
Treated cell pellets were re-suspended in lysis buffer (50mM Tris–HCL pH 7.4,
1mM EDTA, 1% IGEPAL, 0.25% sodium deoxycholate) with the protease inhibitors
1mM AEBSF, 1g/ml leupeptin, and phosphatase inhibitors 1mM sodium ortho-
vanadate, 1mM sodium ﬂuoride. One volume of Laemmli buffer (250mM Tris pH
6.8, 10% glycerol, 4% SDS, 2% -mercaptoethanol, 0.006% bromophenol blue) was
added to the lysate. It was then boiled for 5min, centrifuged and the concentra-
tion of the resultant protein extract was determined using the 2-D Quant Kit (GE
Lifesciences, Bucks, UK) according to manufacturers’ instructions.
Ten micrograms of each protein extract were separated by 10% SDS-
polyacrylamide gel electrophoresis. The proteins were then transferred to a
nitrocellulose membrane using a vertical cell tank transfer system (Bio-Rad, Hert-
fordshire, UK). The membranes were incubated with 1:1000 dilutions of primary
antibodies speciﬁc to MGMT (Abcam, Cambridge, UK), MPG (Sigma–Aldrich, Dorset,
UK), p53, phosphoser15-p53 or -actin (Cell Signalling Tech, New England Biolabs,
Herts, UK). They were then stringently washed and a secondary goat anti-rabbit
IgG-horseradish peroxidase (HRP) conjugate antibody (diluted 1:1000) or rabbit
anti-mouse-HRP antibody (diluted 1:20,000; Abcam, Cambridge, UK) were applied
as required. Following washes to remove all excess and non-speciﬁcally bound anti-
bodies, the membrane was developed with the ECL chemiluminescence detection
agent (GE Lifesciences, Bucks, UK) and subsequently viewed under the Chemidoc
XRS system (Bio-Rad, Hertfordshire, UK). Average band density analysis was per-
formed on the Quantity One Vs 4.6.3 software (Bio-Rad, Hertfordshire, UK) and all
test banddensitieswere normalised against the corresponding-actin banddensity
to compensate for variations in protein loading.
3. Results
3.1. Quantiﬁcation of N7-meG DNA adducts
In order to determine if methyl adducts were present in DNA
samples below the LOEL, mass spectrometry was utilised. As only
0.3% of MMS adducts occur at O6G it was not considered practical
to try and quantify this adduct at such low exposure concentra-
tions. We therefore elected to measure N7-meG adducts, which are
substantially more frequent events following exposure to MMS.
To determine sensitivity, a standard curve of MS signal response
(normalised to the response obtained from the ethylguanine
external standard) was established for concentrations of N7-meG
ranging from 10 to 10,000 fM. This curve was linear and was sub-
sequently used to quantify the level of N7-meG adducts in DNA
samples fromcells treatedwithMMS for24h.As illustrated inFig. 1,
Fig. 1. Concentration of N7-meG DNA adducts detected by mass spectrometry fol-
lowing exposure to MMS.
Fig. 2. (a) Relative fold change inMGMTgene expressionwith time, following expo-
sure to increasing concentrations of MMS. (*) Represents P<0.05. (b) Representative
Western blot for MGMT following a 4 and 6h MMS treatment. Relative fold change
in protein expression represents the ratio of the -actin normalised treated band
density to the un-treated control band density.
exposure toMMS resulted inmeasurable increases inN7-meGDNA
adducts at all doses. Importantly, 0.6g/ml MMS (which lies below
the reported LOEL) resulted in 7.55pM N7-meG. This was a 5-fold
increase above the levels observed in the control samples (1.40pM).
3.2. MGMT and MPG expression
To investigate the MGMT expression induced following expo-
sure to MMS, relative changes in gene expression were quantiﬁed
by real-time RT-PCR (Fig. 2a). AHH-1 cells were exposed to range
of MMS concentrations up to 2g/ml for 1, 2, 4, 6, or 24h in order
to determine the speed at which a cellular response was induced.
However, as can be seen in Fig. 2a, signiﬁcant up-regulation of
MGMT expression was only observed when cells were treated with
0.5 and 1.0g/ml MMS for 4h. These doses resulted in 2.5- and
6.5-fold increases in MGMT gene expression respectively. Despite
the large increases in gene expression at this single 4h time point,
at all further later time points (6 and 24h), MGMT transcriptional
levels returned to base levels. Interestingly, these large increases in
expression were not observed at the higher doses utilised in this
study (1.5 or 2g/ml). When MGMT protein levels were consid-
ered, after 4h exposure to MMS the enzyme levels were reduced
at all doses (Fig. 2b), but by 6h they had increased again, almost to
background levels.
When the MGMT gene expression data after a 4h MMS expo-
sure periodwas overlaidwith the original genemutation frequency
dose–response curve that was previously generated [4], MGMT
expressionwas found tobe signiﬁcantly elevatedatdosesbelowthe
reported pragmatic threshold (Fig. 3). However, at the LOEL dose,
the transcriptional status of this repair enzyme returned back to
the base level.
When the gene expression patterns of MPG in relation to MMS
exposure were investigated just minor ﬂuctuations were observed,
with the only signiﬁcant increase in transcriptional activity occur-
ring at 1.5g/ml MMS after 4h exposure (Fig. 4a). This was a 2-fold
up-regulation; however this increase was not maintained at higher
doses and at 2g/ml MMS for 4h, MPG expression had returned to
basal levels. Additionally, when only the 2g/ml dose was consid-
ered, there again appeared to be an increasing trend in expression
with time that did reach a 1.5-fold up-regulation at 6h, but this
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Fig. 3. Relative fold change in MGMT expression after exposure to increasing
concentrations of MMS for 4h, as compared to the point mutation frequency
dose–responsecurve reported inDoaket al. [4].MF,mutation frequency (thenumber
of 6-thioguanine resistant clones/106 clone-forming cells).
did not reach signiﬁcance and the 24h time point was no differ-
ent to the controls. However, none of these slight variations in gene
expressionwere translated through to the protein level aswe found
that MPG enzyme levels remained the same across all doses after
4 and 6h treatment times (Fig. 4b).
3.3. p53 Activity
As itwas unexpected thatMGMTup-regulationwasnot induced
byMMSat doses above the reported LOEL,we investigatedwhether
p53 activation may have been responsible for inhibiting MGMT
expression at the higher doses, as it has been suggested that p53
can repressMGMTexpression. To investigate,we initially examined
the p21 transcriptional proﬁle, a central p53 effector molecule and
therefore an indicator of p53 activity. As illustrated in Fig. 5, a sig-
niﬁcant elevation in p21 gene expression was only detected after
24h exposure to 2g/ml MMS. This suggests p53 activation, but to
further corroborate this event, p53 and phosphoser15-p53 protein
levels were quantiﬁed in extracts obtained from cells treated with
0–2.5g/ml MMS for 1–24h. Over all the doses at each time point,
the level of p53 and phosphoser15-p53 remained steady. Thus, no
Fig. 4. (a) Relative fold change in MPG expression with time, following exposure to
increasing concentrations of MMS. (*) Represents P<0.05. (b) Representative West-
ern blot for MPG following a 4h (top panel) and 6h (bottom panel) MMS treatment.
Fig. 5. Relative fold change in p21 expression with time, following exposure to
increasing concentrations of MMS. (*) Represents P<0.05.
apparent measurable increases in p53 expression or phosphory-
lation were observed with time following increasing exposure to
MMS up to 2.5g/ml (Fig. 6).
4. Discussion
MMS is a model alkylating agent with a high s-value. Conse-
quently, it predominantly reacts with N7G, in fact over 80% of DNA
adducts induced by MMS occur at this position, with the remain-
der arising at N3A (10%) and O6G (0.3%) [6]. This distribution in
DNA lesions is likely to govern the biological consequences follow-
ing exposure to MMS as O6-alkyG is considered to be mutagenic,
while N7-alkylG has a lower genotoxic potential as it is prone to
spontaneous depurination (due to the weakened glycosidic bond)
resulting in an abasic site that if detected is subsequently corrected
by BER. This repair mechanism is error prone, so point mutations
and chromosome aberrations can result as a by-product of the cor-
rectionprocess.However, if these lesions arenot repaired theabasic
sites themselves represent single-strand breaks that can readily
turn into irreparable double-strand breaks by stalling replication
forks [15].
Molecular dosimetry studies have shown that DNA adduct for-
mation in general shows no threshold, with a linear correlation
between adduct formation and exposure dose for several com-
pounds including aﬂatoxin B1, benzo(a)pyrene, methylating and
ethylating agents [20–23]. However, there is some controversy over
this as theoretically it is possible that chemical agents may be pre-
vented from entering the nucleus due to membranes (both cell
and nuclear) and binding to other biomolecules, which may act to
limit the quantity of compound that reaches the DNA and thus DNA
adduct formationmay be expected to demonstrate a NOEL itself. As
yet, this has not been demonstrated experimentally. Indeed in the
current study we were able to detect N7-meG adducts within the
Fig. 6. Representative Western blot for phosphoser15-p53, p53 and -actin follow-
ing treatment with 0–2.5g/ml MMS for 4h. The ratio of phosphoser15-p53 to p53
average band density was calculated after normalisation to -actin.
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NOEL for mutagenicity and this is in agreement with a very recent
report by Swenberg et al. [22]who have demonstrated a linear DNA
adduct response across a wide dose range of MMS in this same cell
line. Consequently, thenon-linearmutagenic responseobserved for
MMS is not due to lack of DNA adducts within the NOEL dose range
and therefore indicates that those adducts present are probably not
being ﬁxed as permanent genetic alterations.
DNA adducts represent biomarkers of exposure, but the fact that
theyarepresent atdoses thatdonot causegeneticdamage indicates
they can be biologically insigniﬁcant perhaps as they are removed
before the lesions are processed into genetic aberrations. Indeed
O6-alkyG is directly repaired by the one-step “suicide” enzyme,
MGMT, with pre-existing MGMT levels in the cell determining its
capacity for repairing O6-alkylG lesions [24]. N7-alkylG adducts
that have not suffered spontaneous depurination are subject to
enzymatic hydrolysis of the N-glycosydic bond by MPG to remove
the adduct leaving an apurinic site that is repaired by BER [25].
In the present study we therefore assessed the gene expression of
MGMT and MPG in relation to MMS exposure.
With regards toMPG, a lack of inducibility followingMMS treat-
ment was observed at both the gene and protein expression levels.
This is not unexpected as it has been well documented that over-
expression ofMPG increases the cytotoxicity of alkylating agents as
it accelerates the rate of formation of apurinic sites and/or strand
breaks resulting in an imbalance in the BER pathway such that
apurinic sites are generated faster than they canbe repaired [13,26].
Our ﬁndings therefore conﬁrm thatMPG is tightly regulated during
exposure to alkylating agents, but despite its expression not being
implicated in contributing to the NOEL of MMS, it still remains pos-
sible that BER is enhanced at low doses through another of the
enzymes involved in this repair pathway.
In contrast, an increasing trend in MGMT expression with dose
(after 4h exposure) was observed within the previously reported
NOEL forMMS.A2.5- and6.5-foldMGMTup-regulationoccurred at
0.5 and 1g/mlMMS respectively, with the highest level of expres-
sion at the dose just below that of the LOEL for MMS induced point
mutations (1.25g/ml). Thus, this boost in MGMT expression at
low doses may be responsible for repairing O6methylG lesions at a
faster rate than they appear resulting in the observed NOEL. Indeed
after 4h exposure to MMS, MGMT protein levels were depleted
by a factor of approximately 50%, suggesting their involvement
in removing methyl groups from DNA and subsequently under-
going proteosomal degradation. However, by 6h the quantity of
enzyme in the cells was elevated to a level similar to un-treated
cells, likely due to the transcriptional up-regulation. The increase
in MGMT gene expression was not maintained after 4h as we
detected no further up-regulation so the initial burst may result
in the synthesis of enough enzyme for the cell to cope with the
damage, this is supported by the fact that after a 24h dose with
1g/ml MMS no point mutations result (Fig. 3) [4]. However, this
is not the case for chromosomal damage as the LOEL for MMS
is 0.85g/ml. The evidence therefore indicates that O6-alkylG is
unlikely to be primarily responsible for the clastogenicity observed
at these lowerdoses, becausedespite thehighMGMTup-regulation
at 1g/ml, at this dose signiﬁcant chromosomal damage can be
detected. This observation supports previous ﬁndings where the
MMS non-linear dose–response curve for chromosomal damage
was the same in an MGMT deﬁcient cell line (MT1) as com-
pared to cells that express the enzyme [4]. Thus removal of
O6-alkyG by MGMT has little inﬂuence on the chromosomal dam-
age related NOEL dose range for MMS, suggesting that O6-alkylG
is not a key clastogenic adduct. Consequently, it appears that at
low doses O6-methylG lesions are responsible for MMS mutagenic-
ity, while N7-methylG may be the predominant cause of MMS
clastogenicity.
Fig. 7. Representative graph demonstrating fold change in MGMT expression with
time following exposure to increasing concentrations of EMS.
It was however unexpected that the increasing trend in MGMT
expression did not continue with the longer incubation periods or
higher concentrations of MMS. With regards to the lengthier treat-
ment times, it is possible that the increase in expression at 1g/ml
at 4h exposure resulted in a dramatic boost in cellular MGMT pro-
tein levels that caused a negative feedback loop (based on DNA
damage signalling), leading to reduced transcriptional activity of
the gene, and thus accounting for the base levels of expression at 6
and 24h 1g/ml treatments. However, this would not account for
the lack of MGMT gene response at 4h with concentrations higher
than 1g/ml, unless at the much higher concentrations alternative
repair pathways are activated in response to the increase in adduct
formation, not only in DNA but also on other biomolecules.
One such pathway involves the p53 tumour suppressor gene
and is particularly interesting in the context of this study as it has
been found to modulate both basal and genotoxic stress induced
MGMT expression. However this regulation courts some contro-
versy as p53 appears to be vital for MGMT up-regulation following
genotoxic insults [9,27,28], yet p53 over-expression inhibits MGMT
expression in vitro and such an association has also been indicated
in vivo [9,29,30].
The AHH-1 cell line we have utilised in this study does har-
bour a heterozygous p53 mutation at the codon 281/282 interface
within exon 8, but it does not inﬂuence the molecules DNA damage
response [31]. Thus, to determine whether or not p53 was involved
in modulating the expression of MGMT in the current study we
ﬁrst monitored the p21 gene expression pattern as it is a key p53
down stream effector molecule. However, no increases in expres-
sionwere observeduntil the cellswere exposed to 2g/mlMMS for
24h. This indicated that at the higher doses, p53 was activated in
response, but this response was delayed as compared to the sharp
loss of MGMT expression and so was not a conclusive indicator of
p53 activity at lower concentrations. We therefore, assessed p53
and phosphoser15-p53 protein levels, but this again did not demon-
strate any measurable increases that could account for modulation
ofMGMTexpression.Hence, the sourceof failure inmaintaining the
MGMT transcriptional up-regulation, particularly with increasing
MMS dose remains unknown.
Interestingly, a similar MGMT expression pattern was observed
when cells were insulted with EMS (representative data shown in
Fig. 7). Our preliminary results demonstrated MGMT up-regulation
only at the NOEL and below for EMS, not at higher concentrations);
but in this case the responsewas lower (a 2-fold increase in expres-
sion) and slightly more delayed as it was only observed after a 6h
exposure time. This difference between MMS and EMS might be
largely due to the fact that although MGMT recognises a range of
alkyl groups as substrates, larger alkyl adducts are removed less
efﬁciently than methyl adducts [8,32]. Hence, the presence of ethyl
adducts may therefore illicit a weaker MGMT response.
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In conclusion, the gene expression of MGMT is substantially
up-regulated at doses that lie within the reported NOEL for MMS
thereby suggesting that it might play a key role in removing DNA
adducts before they are ﬁxed as permanent mutations. However at
doses higher than the LOEL, MGMT expression drops back to base
level. The reason for this is unknown; our initial data does not indi-
cate p53 activation is involved, but at this stage it cannot be ruled
out and further investigation is required. It is possible that MGMT
might simply be the more dominant means of adduct removal at
low dose, while at higher exposure levels alternative DNA repair
pathways are triggered in the cell by the genotoxic responses.
Indeed this has been observed in resistance to the chemother-
apeutic agent BCNU [33]. Additionally, N7-alkylG and O6-alkylG
are substrates for mismatch repair and nucleotide excision repair
particularly when MGMT is overloaded [7,15,34–36], but further
analysis is required to substantiate this theory with regards to
monofunctional alkylating agents.
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